Vee M-26
Vee M-26 - General Information
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Vee M-26 inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Vee M-26 acts primarily in the G2 and S phases of the cycle. [PubChem]
Pharmacology of Vee M-26
Vee M-26 is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Vee M-26 causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA.
Vee M-26 for patients
Vee M-26 Interactions
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. Because of the extremely high binding of teniposide to plasma proteins, these small decreases in binding could cause substantial increases in free drug levels in plasma which could result in potentiation of drug toxicity. Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents. There was no change in the plasma kinetics of teniposide when coadministered with methotrexate. However, the plasma clearance of methotrexate was slightly increased. An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.
Vee M-26 Contraindications
VUMON is generally contraindicated in patients who have demonstrated a previous hypersensitivity to teniposide and/or Cremophor® EL (polyoxyethylated castor oil).
Additional information about Vee M-26
Vee M-26 Indication: Treatment of refractory acute lymphoblastic leukaemia
Mechanism Of Action: Binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Teniposide
Synonyms: Teniposido [Inn-Spanish]; Teniposidum [Inn-Latin]
Drug Category: Antineoplastic Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Teniposide: VeeM-26; Veham-Sandoz; Vehem; Vumon;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 5 hours
Dosage Forms of Vee M-26: Liquid Intravenous
Chemical IUPAC Name: Not Available
Chemical Formula: C32H32O13S
Teniposide on Wikipedia: https://en.wikipedia.org/wiki/Teniposide
Organisms Affected: Humans and other mammals